Cassava sciences announces initiation of an open-label extension study

Austin, texas, oct. 13, 2022 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, today announced the initiation of an open-label extension study. this study is designed to provide no-cost access to simufilam, an investigational drug, to patients with alzheimer's disease who complete either one of cassava sciences' on-going phase 3 studies, which are double-blind, placebo-controlled trials.
SAVA Ratings Summary
SAVA Quant Ranking